Sprague-Dawley rats were treated with 5 mg/kg body weight of phencyclidine (PCP) injected at I ml/kg subcutaneously on three consecutive days at four different stages of gestation. Within IO-30 min after treatment, dams showed some lack of motor coordination and became lethargic. On gestational day 21, all rats were killed by decapitation and brains were dissected and stored from mother and fetus for neurochemical analysis. PCP, dopamine and muscarinic cholinergic receptor binding was measured in membranes prepared from maternal and fetal whole brain. Neurotransmitter concentrations were also measured in the fetal brain homogenates. There was a significant decrease in PCP binding sites in fetal but not maternal brains after maternal PCP injection at gestational days 12-14, 15-17 and 18-20, but not at 9-t I days. Dopamine and muscarinic cholinergic receptor binding was not significantly altered in fetal or maternal brain when compared with vehicle control animals. The whole brain dopamine, 3,4-dihydroxyphenylacetic acid, serotonin, and 5-hydroxyindoleacetic acid concentrations did not show significant change in any group studied. These data indicate that gestational exposure to PCP decreases high affinity binding of PCP in term fetal brain at doses which do not alter maternal PCP receptor binding.
GESTATIONAL EXPOSURE TO PHENCYCLIDINE (PCP) IN RATS DECREASES PCP BINDING SITES IN TERM FETAL BRAIN
is a widely abused psychoactive drug' which is known to interact with several different neurotransmitter systems. PCP and its related analogs inhibit the reuptake and also enhance the release of dopamine, norepinephrine and serotonin both in ~im~~~~*'~**~~*' and in vim. "~'9*20 Kaufman et al. I5 reported that the use of PCP among pregnant women resulted in the birth of neonates exhibiting behavioral abnormalities including temporary rigidity and irritability. Analysis of blood and urine collected from these neonates revealed the presence of PCP.15 Recently, Ahmad et ai.* reported the presence of PCP in serum and brain of rat pups from mothers dosed with PCP during pregnancy. They reported that the Ievels of PCP in pups' brains were much higher than in the corresponding maternal brains. Several investigators have demonstrated the presence of [3H]-PCP binding sites in adult and fetal rat brain homogenates22~24~28*32 and these have been further localized in brain slices by autoradiographic studies. "*23 The main purpose of the present study was to evaluate the effect of prenatal PCP exposure on fetal and maternal PCP binding sites in brain. Other specific neurotransmitter receptors and neurotransmitter ~ncentrations in fetal and maternal brain were also studied.
EXPERIMENTAL PROCEDURES
Pregnant Sprague-Dawley rats weighing 235-250 g were used in this study. Animals were divided into four groups of six animals each. They were housed individualIy in a controlled environment (12 hr 1ight:dark cycle, 20 + 2°C and 50+2% relative humidity). Each of the six rats in the four experimental groups were administered 5 mg PCP/kg body weight (dissolved in 10% methanol in 0.9% saline and injected at 1 ml/kg) injected subcutaneously into the scruff of the neck on three consecutive days. Gestational days of injection were 9, 10 and 11 (group l), 12, 13 and 14 (group 2), 15, 16 and 17 (group 3), and 18, 19 and 20 (group 4). Eight dams received corresponding injections of the methanol-saline vehicte (control group). Two control rats were injected at each of the times corresponding to each experimental group. On gestational day 21 all t Author to whom correspondence should be addressed.
